Medical device manufacturer Terumo Cardiovascular Group has launched its smallest full-size adult oxygenator the Capiox NX19 Oxygenator with UltraPrime Technology. Terumo has already begun the sales of the product in Europe and the U.S. and is planning to expand its sales across Asia and Japan.
The new Capiox NX19 oxygenator is the company’s most advanced product design to date. It helps minimize the impact of cardiopulmonary bypass by reducing hemodilution, minimizing inflammatory response, and providing highly efficient gaseous microemboli (GME) removal.
Key Features of the Device:
- High flow with low priming volume
- Terumo’s exclusive hollow fiber, woven
- Flexible for every setup
- Low minimum operating level
- Xcoating surface coating
- Venous reservoir indicated for VAVD
“The Capiox NX19 oxygenator is the next step in Terumo’s legacy of oxygenator innovation,” said Robert DeRyke, President and CEO of Terumo Cardiovascular Group. “Terumo introduced the world’s first hollow fiber oxygenator in 1982 and remains at the forefront of the industry, developing high-quality products that help save patient lives.”
New UltraPrime technology delivers a priming volume of just 185 mL and maximum blood flow of up to 8 L/min by combining proprietary materials with engineering expertise. Evidence supports the use of lower prime circuits to reduce hemodilution, leading to fewer blood transfusions and lower risk of acute kidney injury (AKI).
The Capiox NX19 oxygenator incorporates Terumo’s new proprietary hollow fibres woven in a unique pattern to provide low prime and surface area reduction while delivering high gas exchange performance, all without increasing pressure drop.
A patent-pending pre-heat-exchanger technology removes air before it enters the highly efficient heat exchanger. This in combination with Terumo’s original self-venting technology and new Prime Assist feature ensures excellent GME removal.